Roles of Radiation Dose and Chemotherapy in the Etiology of Stomach Cancer as a Second Malignancy

Belt-Dusebout, Alexandra W. van den; Aleman, Berthe M.P.; Besseling, Gijs; Bruin, Marie L. De; Hauptmann, Michael; Veer, Mars B. van ‘t; Wit, Ronald de; Ribot, J. G.; Noordijk, Evert M.; Kerst, J. Martijn; Gietema, Jourik A.; Leeuwen, Flora E. van

doi:10.1016/j.ijrobp.2009.01.073

Cited by 89 publications

(59 citation statements)

References 42 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Radiation therapy is a main contributor to solid tumors in HL survivors, although more recent data have linked alkylating chemotherapy to a variety of solid tumors, including lung cancer and gastrointestinal cancers. [2][3][4][5] For selected second malignancies, sex, age at treatment, environmental exposures, and underlying genetic factors also contribute to the increased risks. [6][7][8] Best et al showed 2 variants at chromosome 6q21 to be associated with subsequent malignant neoplasm in survivors of HL treated with radiation therapy as children but not as adults.…”

Section: Second Malignancymentioning

confidence: 99%

“…Case-control studies have shown a significant radiation dose-response relationship for the development of stomach cancer in HL survivors. 2,4 In a population-based study, it was found that HL patients who develop cancer of the transverse colon and stomach experience significantly reduced survival compared with patients with de novo cancers. 22 In addition to radiotherapy, several chemotherapeutic agents, including procarbazine, platinum, and dacarbazine, are associated with an increased risk of gastrointestinal cancer in a dose-related manner.…”

Section: Gastrointestinal Cancermentioning

confidence: 99%

“…22 In addition to radiotherapy, several chemotherapeutic agents, including procarbazine, platinum, and dacarbazine, are associated with an increased risk of gastrointestinal cancer in a dose-related manner. [2][3][4] …”

Section: Gastrointestinal Cancermentioning

confidence: 99%

See 2 more Smart Citations

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

2014

Hematology

View full text Add to dashboard Cite

Long-term survivors of Hodgkin lymphoma (HL) are at an increased risk for a range of late complications, with subsequent malignant neoplasm and cardiovascular disease representing the 2 leading causes of death in these patients. Raising awareness, close follow-up, and adoption of selected early-detection and risk-reduction strategies may help to reduce the adverse impact of these late effects on patients. This chapter reviews known long-term complications of HL therapy, risk factors, and the timing of their occurrence. Where available, data on the efficacy of screening for selected late effects of HL are presented. Current evidence-based and consensus-based recommendations on follow-up of long-term HL survivors are also reviewed. As HL therapy evolves over time, late effects and implications on follow-up of patients treated in the contemporary era should be considered and opportunities for future research should be explored. Learning Objectives• To review the risk of and risk factors for late effects after HL therapy • To discuss data on the efficacy of screening strategies for selected late effects of HL • To summarize current follow-up recommendations for longterm HL survivors

show abstract

Section: Second Malignancymentioning

confidence: 99%

Section: Gastrointestinal Cancermentioning

confidence: 99%

See 1 more Smart Citation

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

2014

Hematology

View full text Add to dashboard Cite

show abstract

“…Rather, a supplemental control matched on type of initial cancer was selected for case-control sets, in which none of the selected controls had the same type of first cancer, to allow for analyses restricted to matched sets with the same primary malignancy (28,29). A recent case-control study examining radiation dose and chemotherapy as risk factors for second stomach cancer was nested in a combined cohort of survivors of Hodgkin lymphoma and testicular cancer and did not match on primary cancer site (43). Future studies should carefully consider the pros and cons of including specific matching factors in the design phase.…”

Section: Nested Case-control Studiesmentioning

confidence: 99%

Methods to Assess Adverse Health-Related Outcomes in Cancer Survivors

Oeffinger

Leeuwen

Hodgson

2011

Cancer Epidemiology, Biomarkers &Amp; Prevention

Self Cite

View full text Add to dashboard Cite

Designing a study focused on adverse health-related outcomes among cancer survivors is complex. Similarly, reading and interpreting the findings of a survivorship-focused study requires an appreciation of the complexities of study design, potential biases, confounding factors, and other limitations. The topic areas are broad-study design, comparison populations, measures of risk, key health outcomes of interest, potential modifying factors to consider. With brevity, this article includes basic information to consider within these areas as well as examples and concepts intended to advance the science of survivorship research and encourage further reading and exploration. Cancer Epidemiol Biomarkers Prev; 20(10); 2022-34. Ó2011 AACR.

show abstract

“…Observations linking RT-related late toxicities to both the RT dose and the volume of normal tissue irradiated have sparked investigators to explore avenues to reduce the intensity of therapy in order to minimize the risk of toxicity while still preserving oncologic efficacy. 3,[7][8][9][10] Technological advances in RT planning and delivery have also provided innovative solutions for minimizing the radiation exposure of normal tissue.…”

mentioning

confidence: 99%

Contemporary Radiation Therapy in Combined Modality Therapy for Hodgkin Lymphoma

Narang

Terezakis

2015

J Natl Compr Canc Netw

View full text Add to dashboard Cite

The advent of effective combination chemotherapy markedly changed the management of Hodgkin lymphoma, establishing combined modality therapy as the standard of care for most patients with this disease. In response, significant interest has been shown in refining the delivery of radiation in the combined modality setting such that toxicity is minimized while still preserving disease control. An understanding of the way in which radiation treatment fields, prescription dose, and advanced technology have evolved to accomplish these goals is critical. Moreover, fluency in the clinical literature exploring contemporary questions, such as the omission of radiation and response-based treatment, is equally important. Knowledge of these topics will yield both an appreciation of the value of radiation in the combined modality setting and the ability to better customize treatment regimens to individual patients. (J Natl Compr Canc Netw 2015;13:597-605)

show abstract

Roles of Radiation Dose and Chemotherapy in the Etiology of Stomach Cancer as a Second Malignancy

Cited by 89 publications

References 42 publications

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects

Methods to Assess Adverse Health-Related Outcomes in Cancer Survivors

Contemporary Radiation Therapy in Combined Modality Therapy for Hodgkin Lymphoma

Contact Info

Product

Resources

About